Skip to main
FDMT

FDMT Stock Forecast & Price Target

FDMT Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

4D Molecular Therapeutics is a biotechnology company with a diversified gene therapy product pipeline that has shown promise in late-stage clinical trials for wet AMD and DME. The company has strong financial backing and a potential first-in-class gene therapy drug, 4D-150, with a favorable safety profile and potential for significant treatment burden reduction. However, risks to the company's investment thesis include failure to secure capital resources and potential limitations in achieving peak commercial revenue estimates.

Bears say

4D Molecular Therapeutics is facing several risks that may impact its ability to achieve its target price. These risks include the potential for clinical setbacks, as well as manufacturing and regulatory challenges. While the company has demonstrated delivery in various target tissues, the novelty and complexity of gene therapy products could lead to delays and unforeseen safety issues. Furthermore, while the company's pipeline is focused on larger indications with potential for commercial success, there is no guarantee that it will receive significant market share. As a result, our financial analysis suggests a negative outlook for 4D Molecular Therapeutics' stock.

FDMT has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 4D Molecular Therapeutics (FDMT) Forecast

Analysts have given FDMT a Strong Buy based on their latest research and market trends.

According to 6 analysts, FDMT has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

4D Molecular Therapeutics (FDMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.